Letter: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial

J Urol. 2024 Oct;212(4):622-623. doi: 10.1097/JU.0000000000004095. Epub 2024 Jun 19.

Authors

Rachel Passarelli¹, Saum Ghodoussipour¹, Vignesh T Packiam¹

Affiliation

¹ Section of Urologic Oncology Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.

PMID: 39254130
DOI: 10.1097/JU.0000000000004095

No abstract available

Publication types

Letter
Clinical Trial, Phase III

MeSH terms

Adjuvants, Immunologic / administration & dosage
Adjuvants, Immunologic / therapeutic use
Administration, Intravesical
BCG Vaccine* / administration & dosage
BCG Vaccine* / therapeutic use
Follow-Up Studies
Humans
Neoplasm Invasiveness
Treatment Outcome
Urinary Bladder Neoplasms* / drug therapy
Urinary Bladder Neoplasms* / pathology

Substances

BCG Vaccine
Adjuvants, Immunologic